USPTO serial 79081065
ECTYCELL
Reviewed by CopyMark Law Group
Reg. 3939980Status 404
- Filing date
- Status date
- Registration date
- Apr 5, 2011
- Examiner
- CLAYTON, CHERYL A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ECTYCELL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey H. Greger
JEFFREY H. GREGER Lowe Hauptman Ham & Berner, LLP2318 Mill RoadSuite 1400Alexandria, VA 22314Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical, biotechnological and bacteriological products for use in industry, science, agriculture, horticulture, namely, chemicals used for industrial purposes, polypeptides for in vivo and in vitro genetic engineering, nucleic acid vectors, natural and engineered meganucleases and endonucleases; chemical, biochemical, biotechnological and bacteriological products for use in research and testing laboratories, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological preparations for scientific purposes namely, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; diagnostic preparations for scientific purposes; proteins being raw materials | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical, veterinary and sanitary products, namely, foods, dietetic beverages, and beverages for medical purposes, nutritional supplements for medical use, cultures and preparations of microorganisms for medical, pharmaceutical and veterinary purposes, bacteriological preparations for medical, pharmaceutical and veterinary purposes, medicines for veterinary purposes derived from or validated with stem-cell derived biologicals and for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, medicines for human purposes derived from or validated with stem-cell derived biologicals and for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, biological preparations for medical, pharmaceutical and veterinary purposes for grafts, cell therapy and regenerative medicine, for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical and biochemical preparations for medical, pharmaceutical and veterinary purposes for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, chemical-pharmaceutical preparations for treating genetic diseases including proliferative disorders such as cancer, immunomodulatory disorders such as immunodeficiency and autoimmune syndromes, single gene disorders such as autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, Y-linked and Mitochondrial linked diseases, multifactorial and polygenic disorders, infectious diseases including those caused by pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, diagnostic preparations for medical purposes | SECTION 71 - CANCELLED | — |
| 009 | Scientific apparatus and instruments used in the implementation of biochemical analysis and molecular biology techniques, namely, automated biochemical analyzer, automated protein production and protein purification devices, biochemical, biological automated assay devices, nucleic acid break analyzer, devices for protein-nucleic acid interaction analysis; scientific apparatus and instruments for the mapping of all molecules' biological activities; data processing apparatus; multimedia products, namely, blank magnetic, blank optical, blank image and blank sound recording media; software for recording scientific and medical data on an on-line computer database in the field of pharmaceuticals and biotechnology, for simulation and design of biological and chemical products; apparatus and instruments for non-medical diagnosis, namely, computer hardware, microscopes, spectrometers | SECTION 71 - CANCELLED | — |
| 042 | Scientific research and industrial research in the field of genome engineering, protein engineering; scientific research in the field of genetics, medical, pharmaceutical and veterinary research; scientific research in the field of biology, biochemistry, molecular biology, bacteriology; scientific analysis; scientific research and development of biochemical, biological and molecular biology analysis techniques; research and development of new molecules for industrial use, scientific laboratory services, namely, isolation and preparation of stem cells; laboratory services, namely, imaging core lab services; engineering services, particularly technical project planning; computer programming, computer software and multimedia software design and development | SECTION 71 - CANCELLED | — |
| 045 | Intellectual property licensing; patent licensing | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CELLECTIS
- Other trademarks owned by CELLECTIS
- Other trademarks owned by CELLECTIS
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named ECTYCELL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 17, 2020 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Apr 17, 2020 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| May 2, 2019 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Sep 14, 2018 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 19, 2018 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jul 19, 2018 | INPC | INVALIDATION PROCESSED | — |
| Jul 10, 2018 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Nov 10, 2017 | C71T | CANCELLED SECTION 71 | — |
| Mar 27, 2014 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 19, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 28, 2013 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 29, 2011 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 29, 2011 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 5, 2011 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 5, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 18, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 29, 2010 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 13, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 13, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 19, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 19, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 19, 2010 | ALIE | ASSIGNED TO LIE | — |
| Nov 4, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 18, 2010 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 7, 2010 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 7, 2010 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 5, 2010 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 4, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2010 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 22, 2010 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |